… group, the median duration of atezolizumab treatment was 24.1 weeks and the median
duration of nab-paclitaxel treatment was 22.1 weeks. For patients in the placebo–nab-paclitaxel …

… carboplatin plus paclitaxel and carboplatin plus nab-paclitaxel)… of the atezolizumab plus
nab-paclitaxel combination in the … of nab-paclitaxel and the combination with atezolizumab on …

… treatment groups in the intention-to-treat population but suggests a clinically meaningful
overall survival benefit with atezolizumab plus nab-paclitaxel … , atezolizumab plus nab-paclitaxel …

… We aimed to assess the efficacy and safety of atezolizumab plus chemotherapy (carboplatin
plus nab-paclitaxel) versus chemotherapy alone as first-line therapy for patients with stage …

… Therefore, this study systematically reviewed the RCTs of combined atezolizumab and
nab-paclitaxel in the treatment of TNBC and synthesize the evidence-based results on its …

… may enhance atezolizumab’s antitumor activity. The phase III IMpower130 study reported
that the addition of atezolizumab to carboplatin and nab-paclitaxel for the first-line treatment of …

… of treatment in the atezolizumab plus nab-paclitaxel group … atezolizumab plus nab-paclitaxel
as the preferred treatment … may be treated first with atezolizumab plus nab-paclitaxel [10]. …

… clinical outcome than nab-paclitaxel as the first-line treatment for advanced … of atezolizumab
to nab-paclitaxel would not be a cost-effective strategy. Lowering the price of atezolizumab …

… supporting the use of atezolizumab and nab-paclitaxel in the treatment of metastatic PD-…
atezolizumab to nab-paclitaxel prolonged progression-free survival in both the intention-to-treat …

… atezolizumab and nab-paclitaxel (A+nP) vs placebo and nab-paclitaxel as first-line treatment
for mTNBC, met its co-primary PFS endpoint in the intention-to-treat (ITT) population and in …